The FDA announced on July 21, 2022, that Teva Pharmaceuticals USA Inc. is recalling Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets due to failed dissolution specifications. The agency stated the recall was voluntary and initiated by the firm.
How to tell if you have it
- Brand: Teva Pharmaceuticals
- Product: Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg
- Packaging: 30-count bottles, Rx Only
- NDC: 58544-692-30
- Lot Code: 1411596A
- Expiration Date: 09/22
- Quantity: 5677 bottles
The hazard
The recall addresses failed dissolution specifications, where the product fell below specification limits for dissolution. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show Teva Pharmaceuticals USA, Inc. has 59 other recalls on record since April 2, 2012. Other recent recalls of similar products include Teva recalling traZODone 50mg tablets with foreign tablets risk (Aug. 24, 2026) and Teva Octreotide Acetate 30mg Kit due to sterility risk (April 24, 2026). Other recent recalls of similar products include Inventia Chlorthalidone Recall for failed dissolution specs (Sept. 3, 2026) and Novartis Recalls Diovan 160mg Tablets due to failed dissolution specifications (Aug. 4, 2026).